Altor BioScience

About:

Altor BioScience researches and develops immunotherapeutic agents for the treatment of cancer, viral infections and autoimmune diseases.

Website: http://www.altorbioscience.com

Twitter/X: altorbiocorp

Top Investors: Sanderling Ventures, Techno Venture Management

Description:

Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and autoimmune diseases. It offers STAR Fusion Reagents for diagnosing and targeting cancer and viral infections; and STAR Multimer Reagents for research and design of anti-cancer and anti-viral vaccine. The company's products in clinical stage include a monoclonal antibody that prevents and treats staphylococcal infections in premature neonates; and STAR-Ck or ALT-801, an anti-cancer drug. It also has products in various development stages, such as fusion agents for cancer and viral infections, immunotherapeutics against staphylococcal infections, gene therapy for cancer, and multimers reagents. In addition, the company provides products for detecting novel disease targets. Its products are used in the direct and quantitative detection of endogenous peptide antigens' presentation on diseased cells and tissues. The company was founded in 2002 and is headquartered in Miramar, Florida.

Total Funding Amount:

$108M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Miramar Beach, Florida, United States

Founded Date:

2002-01-01

Contact Email:

peterrhode(AT)altorbioscience.com

Founders:

Hing C. Wong

Number of Employees:

11-50

Last Funding Date:

2017-03-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai